Latest News | Lupin Inks Pact with Exeltis to Promote Solosec Drug in US
Get latest articles and stories on Latest News at LatestLY. Drug maker Lupin on Thursday said its US-based unit has inked a pact with Exeltis Inc to promote Solosec, a drug used to treat bacterial vaginosis in women.
New Delhi, Jan 27 (PTI) Drug maker Lupin on Thursday said its US-based unit has inked a pact with Exeltis Inc to promote Solosec, a drug used to treat bacterial vaginosis in women.
Also Read | Union Budget 2022-23: Rise in Old-Age Pension, Re-Engaging Seniors Among Demands.
As part of the tie up, Exeltis will promote Solosec along with its existing line of women's health products.
Solosec is indicated for the treatment of bacterial vaginosis in adult women and trichomoniasis in adults, a common non-viral, curable sexually transmitted infection in the US.
Also Read | Vivo Y75 5G With Dimensity 700 SoC Launched in India at Rs 21,990.
"This partnership will expand the reach of Solosec, allowing more healthcare providers to be aware of its benefits, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis," Lupin CEO Vinita Gupta noted.
Exeltis CEO Salustiano Perez said the addition of Solosec fits precisely within its current portfolio of products, enhancing commercial strategy, and offering numerous solutions to customers and their patients."
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)